Abstract：Objective: To evaluate the efficacy and safety of bepotastine besilate in the treatment of primary acquired cold urticaria (PACU). Method: The selected PACU patients were randomly divided into experimental group and control group, were treated with benzenesulfonyl bepotastine besilate and placebo treatment, treatment for two weeks of pruritus and wheal response to cold stimulation test were observed, and the cold water or cold air to stimulate the emergence of clinical symptoms. Result: The itchy wheal reaction cold stimulation test and rewarming in 20 min patients with PACU in cold water or air after the wheal reaction and pruritus compared with the placebo group had significant difference (P<0.05). The incidence of adverse reactions was low. Conclusion: Mizolastine is safe and effective in the treatment of primary acquired cold urticaria.
田志兰,张良岐,侯俊荣,马静,郭雯. 苯磺贝他斯汀治疗原发性获得性寒冷性荨麻疹的有效性研究[J]. 河北医学, 2017, 23(12): 2013-2015.
TIAN Zhilan, ZHANG Liangqi, HOU Junrong, et al. Research on the Effectiveness of Bepotastine Hesilate in the treatment of Primary Acquired Cold Urticaria. HeBei Med, 2017, 23(12): 2013-2015.
2017, Vol. 23 
冀公网安备13080202000677号